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donor sources.
A risk-adapted treatment strategy is crucial to improve
the outcome of pts with HRHD. Our policy is to offer a hap-
loidentical HCT to adult pts lacking a matched donor in the
appropriate time according to clinical indications
(www.leukemianet.org, www.ebmt.org). This policy is inte-
grated in ongoing protocols for primary disease.
Methods: Here we are reporting the intention-to-treat
(ITT) analysis of HCT in all consecutive HRHD pts
referred to our Institution between January 2004 and
June 2012.
Results: Indication to HCT was given to 611 pts (median age
49 y, range 10-76; male 394), 120 pts (20%) received
a transplant from a MRD; 187 pts (30%) activated a MUD
search; 118 pts (19% of total pts, 63% of MUD searching)
received a MUD transplant; 12 pts (2%) received a umbilical
cord blood unit. Overall, 237 pts received a haplo-HCT (49%).
The median time from indication to HCT was 87 days. The
median time from indication to activation was 12 days and
the median time from activation to HCT was 114 days (range
22-824). Lack of donor was not a limiting factor. Age was not
a limiting variable to HCT execution: 107 patients (out of 487
SCT e 22%) were in the 60-69 range of age. The overall
survival (OS) analysis in ITT for the entire populationwas 43%
at 2 years, with a median time of survival of 767 days. The
2yOS in pts transplanted in CRwas 60%, in pts transplanted in
PD is 25% (p <0.001).
The OS according to donor source (MRD vs MUD vs
haplo-HCT) was comparable (p¼ns) in pts transplanted in
CR.
The 2-year OS in pts affected by acute myeloid leukemia
was 66%, 60% and 13% for patients transplanted in CR1, >CR1
and PD, respectively. The outcome analysis (OS, relapse
incidence, transplant related mortality) per donor source
was comparable (p¼ns) within CR setting.
Conclusion: For many pts with HRHD, HCT from a MRD
provides the best chance for long-term survival. However,
only approximately 30% of individuals have a MRD. In our
experience, haplo-HCT offers a concrete option of cure to
HRHD pts: outcome results are superimposable to MRD
and MUD in pts in CR at HCT. In ITT analysis, 80% of
candidate pts received an HCT as a potential immuno-
therapy. All patients affected by HRHD, for whom an HCT
is part of their therapeutic program, should proceed with
a well-timed HCT whatever the stem cell source, and in
the absence of a fully HLA-compatible donor the option of
a haploidentical donor should be simultaneously consid-
ered.27
The Schedule and Dose of Alemtuzumab Determine the
Incidence of Mixed Chimerism in Pediatric Patients
Undergoing Reduced Intensity Conditioning Allogeneic
Hematopoietic Cell Transplantation
Rebecca A. Marsh 1, Mi-Ok Kim 2, Chunyan Liu 3,
Denise Bellman 1, Laura Hart 3, Michael B. Jordan 4,
Jack Bleesing 5, Parinda A. Mehta 1, Sonata Jodele 1,
Kasiani Myers 1, Ashish Kumar 1, Michael Grimley 1,
Stella Davies 1, Lisa Filipovich 6. 1 Bone Marrow Transplantation
and Immune Deﬁciency, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 2Division of Biostatistics and
Epidemiology, Cincinnati Children’s Hospital Medical Center;
3 Cincinnati Children’s Hospital Medical Center; 4 Cincinnati
Children’s Hospital Med Ctr, Cincinnati, OH; 5 BMT/Immunodeﬁciency, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH; 6Division of Bone Marrow
Transplantation & Immune Deﬁciency, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH
Introduction: Reduced intensity conditioning (RIC) alloge-
neic hematopoietic cell transplantation (HCT) with alemtu-
zumab, ﬂudarabine, and melphalan can be associated with
high incidences of mixed chimerism (MC). We have previ-
ously observed a signiﬁcant effect of dose and timing of
alemtuzumab on incidences of MC in patients with HLH.
Here we sought to determine the effects of alemtuzumab
schedule and dose on chimerism in a large cohort of patients
treated with RIC.
Methods: We performed 187 RIC HCT in 186 pediatric
patients between 2004 and March, 2012. Fourteen patients
were excluded because of regimen alterations due to
illness or intolerance (n¼13) or malignancy relapse (n¼1).
All patients received ﬂudarabine 150mg/M2 (1mg/kg if
<10kg) divided over days -8 to -4 or -7 to -3, and
melphalan 140mg/M2 (4.7mg/kg if <10kg) on day -3 or -2.
RIC HCT procedures were divided into 3 groups based
upon the timing and dose of alemtuzumab. The distal
group received alemtuzumab with a dose escalation
schedule of 3mg/10mg/15mg/20mg or 3mg/10mg/10mg/
10mg starting on day -23, -22, or -21. The intermediate
group received 1mg/kg alemtuzumab divided over 5 days
starting on day -14. The proximal group received alem-
tuzumab beginning on days -12, -11, -9 or -8, with either
of the dosing schemas. The distal group was further
subdivided based on cumulative alemtuzumab doses of
greater or less than 3mg/kg (the median dose/kg). The
cumulative incidences (CI) of MC were compared.
Results: A 75% CI of MC was observed in the proximal
group, versus 32% and 39% of patients treated with the
intermediate and distal schemas (p<0.0001). Within the
distal group, the CI of MC was 67% in patients who received
>3mg/kg and 28% in patients who received <3mg/kg
(p¼0.008).
Conclusion: Proximal dosing of alemtuzumab with relation
to graft infusion and higher doses of alemtuzumab signiﬁ-
cantly increase the incidence of mixed chimerism.28
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Radioimmunotherapy (RIT) has been employed to
decrease relapse after hematopoietic cell transplantation
